The evolution of thalidomide and its IMiD derivatives as anticancer agents.
about
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungsMechanism of action of lenalidomide in hematological malignanciesCereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideThalidomide analogues as anticancer drugsEnhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsPrimary cutaneous lymphomas: diagnosis and treatmentNovel strategies to target the ubiquitin proteasome system in multiple myelomaRegulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin LigasesCTLA-4 blockade in tumor models: an overview of preclinical and translational researchNovel molecular pathways in Gorham disease: implications for treatmentStructure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideStructural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligaseVaccines versus immunotherapy: overview of approaches in deciding between optionsRecent clinical studies of the immunomodulatory drug (IMiD) lenalidomideEarly experience with novel immunomodulators for cancer treatmentAn erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndromeDRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradationLenalidomide for the treatment of B-cell lymphoma.Emerging drugs for chronic lymphocytic leukaemia.CRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis.Selective leukemic-cell killing by a novel functional class of thalidomide analogsImmunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyThe role of lenalidomide in the management of myelodysplasia with del 5q.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.Pomalidomide is active in the treatment of anemia associated with myelofibrosisLenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.A phase-2 trial of low-dose pomalidomide in myelofibrosis.Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS.Phase I study of oral lenalidomide in patients with refractory metastatic cancerInhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Ribosomopathies: human disorders of ribosome dysfunction.Cancer and the tumor microenvironment: a review of an essential relationship.
P2860
Q21089606-853AEEB7-C4B8-48F1-8A5D-27B3DA62A4C3Q21198872-18EC7979-9AB5-4CE8-AEF3-DE04BBFA0141Q24614147-79271280-7F9E-4205-A72F-4794A35A3AD3Q24670383-FF6B64F5-423B-49B0-93AD-52A42A0DEA8CQ24685895-567AA440-4A20-4E83-A645-0FD43525977CQ26772207-5A123049-3A34-4714-9207-506891D6857FQ26773246-E7251D29-8E80-4D6B-814C-C052DC91DAE6Q26799441-46781E15-863E-42AB-9E32-38830FD2FB12Q26992295-0C8C8519-8E7D-4959-A039-FBD3167C436FQ27005629-9E4E1668-D8DD-44D3-9EB7-764BF74B1584Q27684738-F98D4929-2564-4F2A-BEF8-9472F4806086Q27704179-ABA7FB11-EDDA-465E-B1E6-C2E806AF34CAQ28085434-9FE18ECA-2A92-498E-A627-8D459614EEC8Q28192646-69C51DF9-A7AB-4F3B-AF78-8AE80BFE6CC0Q28241744-A15CF14B-2FE2-4C98-BD23-5C7B0D8AD55AQ28472171-2A76A077-342D-4462-8B78-3122F327F586Q28830958-D570D020-64CC-4C94-9EAE-94F077B3843AQ30249007-BB4B3DDE-546A-4EAB-8DB4-EE84C3889766Q30353154-7821A33F-21AC-4A54-9B20-7E6021AFE471Q30362741-69F51A7E-F2E3-42A7-AB91-569E6A8828DAQ30479632-9E0DA3A4-A147-42FB-8746-65139341DB4BQ30659342-356CE32B-3514-487B-B8A5-681A64F8758CQ33378398-FE5C1ABB-D15E-4370-91B9-321086E29F66Q33379562-39B7F46F-BA54-4F60-9617-DDDC96475BC0Q33385644-93165B9D-6CC8-4CD0-BCC6-17D552F89CD8Q33386057-EBADA71A-B5D5-447B-8A30-6EB5D43D1F27Q33386405-DF88B2FA-9EA0-4D66-AAFE-E01723B21E85Q33388648-2F0BBEC2-D2F4-4D34-A256-0BDF7ED255E7Q33392689-03C2EA54-15AB-44B2-991D-4B82F3FA26A3Q33427312-61BBF665-CBB5-4902-9DB7-3775DB0F89DAQ33436247-4BEF027D-890F-4895-97C7-B2356B838E32Q33500473-482A233B-92EB-4F87-9BF8-E6E1A52624ABQ33535799-D89AA73C-9928-4DBB-B68A-4D1D61615DE9Q33600521-6096C78F-F489-472C-9005-26B28D514420Q33616683-74E3B55C-0B09-414C-9D94-8C44536FDE4BQ33642278-8A38095D-9D03-4F43-B92F-41E163F34C43Q33655628-C4D83386-0A09-4708-97A8-EA270EBBC9ADQ33707411-34B450F8-FCBB-4153-BB34-E7D73F8602C1Q33806050-560DF97E-FA75-4870-9FF2-C9B268DF4909Q33806357-56644C3B-90E2-47A0-B73C-5EC17ED3697C
P2860
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@en
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@nl
type
label
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@en
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@nl
prefLabel
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@en
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@nl
P2093
P356
P1476
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
@en
P2093
Angus G Dalgleish
J Blake Bartlett
Keith Dredge
P2888
P304
P356
10.1038/NRC1323
P407
P577
2004-04-01T00:00:00Z